Ainhoa R. M.
- Country
- Spain
- Department
- Cardiology
Research Overview
- Calcifediol Monohydrate Supplementation to Reduce Myocardial Fibrosis in Patients with Acute Myocarditis and Low 25‑OHD: A Multicenter Randomized Controlled Trial
- A Phase 2b/3, Adaptive, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Danicamtiv in Participants with Symptomatic Genetic and Familial Dilated Cardiomyopathy (KINSHIP-DCM).
Data & Insights
Has run more than one trial at 1 of 42 partner sites.
Specializations
Atherosclerotic Cardiovascular Disease
The investigator concentrates on the prevention and management of Atherosclerotic Cardiovascular Disease in patients with elevated lipoprotein(a) and associated metabolic risk factors.
- Elevated Lipoprotein(a)
- Primary prevention
- Statin optimization
- Lipid‑targeted antibodies
Research includes risk stratification and novel lipid‑lowering strategies.
Heart Failure
Focused on both Heart Failure with Reduced Ejection Fraction and Heart Failure with Preserved Ejection Fraction, exploring therapeutic pathways that mitigate ventricular remodeling.
- HFrEF
- HFpEF
- Cardiac resynchronization therapy
- Neurohormonal modulation
Emphasis on early detection in genetically predisposed carriers.
Cardiac Arrhythmias
Investigates the clinical impact of Atrial Fibrillation in high‑risk cohorts, including anticoagulation strategies for patients unsuitable for oral agents.
- Anticoagulation alternatives
- Catheter ablation
- Risk scoring
- Left atrial remodeling
Studies address stroke prevention and rhythm control.
Cardiomyopathies
Research spans genetic and infiltrative cardiomyopathies such as Hypertrophic Cardiomyopathy, Dilated Cardiomyopathy, and Transthyretin Amyloid Cardiomyopathy.
- Gene‑targeted therapy
- TTR stabilizers
- Phenotypic screening
- Family screening programs
Trials evaluate disease‑modifying agents and early therapeutic intervention.
Metabolic‑Cardiovascular Interface
The investigator addresses the intersection of metabolic disorders—Obesity, Type 2 Diabetes, and Non‑alcoholic Steatohepatitis—with cardiovascular risk.
- Weight‑loss pharmacotherapy
- GLP‑1 receptor agonists
- NASH resolution
- Renal‑cardiac outcomes
Focus on integrated management to reduce atherosclerotic burden.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.